iNtRON Biotechnology acquire U.S. FDA’s Orphan Drug Designation for Endolysin

Published: 2018-06-28 16:27:00
Updated: 2018-06-28 16:31:37

iNtRON Biotechnology(CEO Kyung-Won Yoon), a new biologic developing company, announced on the 26th that its currently-developing bacillus anthracis based on endolysin called ‘N-Rephasin BAL200(hereinafter referring to BAL200)’ acquired Orphan Drug Designation(ODD) from the U.S. Food and Drug Admi...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Most Read News

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.